MARX Biotech , Ltd. Receivables

MARX Biotech , Ltd. (7731.TWO) currently reports a receivables of $190M as of June 2026. That compares with $90M in the prior-year period — up 112.7% year over year. Use the charts on this page to explore MARX Biotech , Ltd.'s receivables history and peer comparisons.

MARX Biotech , Ltd.'s receivables increased from $90M to $190M — a 112.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MARX Biotech , Ltd. reported $190M in receivables as of June 2026. That compares with $90M in the prior-year period — up 112.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $190M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MARX Biotech , Ltd., and consider following 7731.TWO for alerts when major investors trade the stock.

MARX Biotech , Ltd. is classified in the Consumer Discretionary sector. On receivables, it currently shows $190M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Consumer Discretionary are usually more informative than comparing 7731.TWO with unrelated industries.